MX2015011730A - Metodos para tratar la lesion renal aguda. - Google Patents

Metodos para tratar la lesion renal aguda.

Info

Publication number
MX2015011730A
MX2015011730A MX2015011730A MX2015011730A MX2015011730A MX 2015011730 A MX2015011730 A MX 2015011730A MX 2015011730 A MX2015011730 A MX 2015011730A MX 2015011730 A MX2015011730 A MX 2015011730A MX 2015011730 A MX2015011730 A MX 2015011730A
Authority
MX
Mexico
Prior art keywords
methods
kidney injury
kidney
treating acute
acute kidney
Prior art date
Application number
MX2015011730A
Other languages
English (en)
Spanish (es)
Inventor
Richard A Zager
Denni Andress
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2015011730A publication Critical patent/MX2015011730A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/34Genitourinary disorders
    • G01N2800/347Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/70Mechanisms involved in disease identification
    • G01N2800/7019Ischaemia
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/70Mechanisms involved in disease identification
    • G01N2800/7038Hypoxia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2015011730A 2013-03-08 2014-03-10 Metodos para tratar la lesion renal aguda. MX2015011730A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361775174P 2013-03-08 2013-03-08
PCT/US2014/022688 WO2014138738A1 (en) 2013-03-08 2014-03-10 Methods of treating acute kidney injury

Publications (1)

Publication Number Publication Date
MX2015011730A true MX2015011730A (es) 2016-04-04

Family

ID=51492045

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015011730A MX2015011730A (es) 2013-03-08 2014-03-10 Metodos para tratar la lesion renal aguda.

Country Status (10)

Country Link
US (1) US20160015701A1 (enExample)
EP (1) EP2964671A4 (enExample)
JP (1) JP2016512201A (enExample)
CN (1) CN105324395A (enExample)
AU (1) AU2014225320A1 (enExample)
BR (1) BR112015020788A2 (enExample)
CA (1) CA2901922A1 (enExample)
HK (1) HK1220209A1 (enExample)
MX (1) MX2015011730A (enExample)
WO (1) WO2014138738A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160003128A (ko) 2013-04-30 2016-01-08 애브비 인코포레이티드 아트라센탄을 사용하는 지질 프로파일을 개선시키기 위한 방법
CN107106522A (zh) * 2014-11-07 2017-08-29 艾伯维公司 使用液体潴留的预测因子治疗ckd的方法
EP3235496A1 (en) 2016-04-19 2017-10-25 Noorik Biopharmaceuticals AG Treatment of acute renal failure
MY192385A (en) * 2016-10-05 2022-08-18 Mitobridge Inc Methods of treating acute kidney injury
KR102177349B1 (ko) * 2018-02-13 2020-11-12 서울대학교병원 체세포 복제 효율 증진용 조성물
US10978176B2 (en) 2018-06-29 2021-04-13 pulseData Inc. Machine learning systems and methods for predicting risk of renal function decline
CA3160148A1 (en) * 2019-11-06 2021-05-14 Northwestern University Inhibition of the ve-ptp phosphatase protects the kidney from ischemia-reperfusion injury
KR20230015874A (ko) * 2019-12-17 2023-01-31 치누크 세라퓨틱스, 인크. 아트라센탄에 의해 iga 신장병증을 치료하는 방법
US20220304979A1 (en) * 2019-12-17 2022-09-29 Chinook Therapeutics, Inc. Methods of reducing disease flares
US20230270718A1 (en) * 2020-04-10 2023-08-31 Chinook Therapeutics, Inc. Methods of treating diabetic kidney disease
CN113209111A (zh) * 2021-05-14 2021-08-06 上海海糖生物医药科技有限公司 一种褐藻寡糖的应用
CN115005157B (zh) * 2022-06-02 2023-12-26 上海交通大学医学院附属新华医院 一种低氧致急性肾损伤动物模型的构建方法
CN116731117B (zh) * 2023-06-19 2024-05-10 武汉大学 Kim-1靶向性多肽及其在急性肾损伤中肾靶向性的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5273961A (en) * 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure
US20060100743A1 (en) * 2004-04-23 2006-05-11 Renal Diagnostic Inc. Automated non-invasive real-time acute renal failure detection system
US20060205733A1 (en) * 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
US9255931B2 (en) * 2010-06-24 2016-02-09 Morehouse School Of Medicine Method and compositions for the treatment and detection of endothelin-1 related kidney diseases

Also Published As

Publication number Publication date
CA2901922A1 (en) 2014-09-12
AU2014225320A1 (en) 2015-08-06
EP2964671A4 (en) 2016-08-31
CN105324395A (zh) 2016-02-10
BR112015020788A2 (pt) 2017-10-10
JP2016512201A (ja) 2016-04-25
HK1220209A1 (zh) 2017-04-28
EP2964671A1 (en) 2016-01-13
US20160015701A1 (en) 2016-01-21
WO2014138738A1 (en) 2014-09-12
WO2014138738A8 (en) 2015-12-30

Similar Documents

Publication Publication Date Title
HK1220209A1 (zh) 治疗急性肾损伤的方法
FIC20250028I1 (fi) Eplonterseeni, valinnaisesti farmaseuttisesti hyväksyttävän suolan muodossa
NO2025050I1 (no) Acalabrutinib or a pharmaceutically acceptable salt thereof, in combination with venetoclax optionally with or without obinutuzumab
Martel-Pelletier et al. Future therapeutics for osteoarthritis
NO2022059I1 (no) Lenacapavir or a pharmaceutically acceptable salt thereof, in particular lenacapavir sodium
NO2023038I1 (no) Ivosidenib or a pharmaceutically acceptable salt, tautomer, isotopologue or hydrate thereof
NO2025017I1 (no) Acoramidis, and/or a pharmaceutically acceptable salt thereof, especially acoramidis hydrochloride
PH12015502310A1 (en) Pharmaceutical composition, methods for treating and uses thereof
HK1207000A1 (en) Dosage and administration of monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies
HK1223319A1 (zh) 用於治疗或预防眼科病的方法
LT3317301T (lt) Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3
BR112014029705A2 (pt) composto ou sal, medicamento, métodos para inibir quinase de janus em um mamífero, e para a profilaxia ou tratamento de doenças autoimunes, e, uso de um composto ou sal
BR112015027281A2 (pt) combinações de dosagens para reduzir respostas imunológicas humorais indesejadas
HK1252816A1 (zh) Tlr8激活剂治疗癌症的应用
HK1243430A1 (zh) 通过施用il-6r拮抗剂治疗乾眼病的方法
CL2013003143A1 (es) Uso de compuestos derivados de fenilaminopirimidinilo, un enantiomero o una sal farmaceuticamente aceptable del mismo para reducir la viabilidad de celulas de mieloma multiple en un estado de celulas no erspondedoras a il-6 y/o que tienen un fenotipo cd45-.
PH12016500042A1 (en) Stabilized pharmaceutical dosage forms comprising atrasentan
SG11201506358PA (en) Anti-cdh3 humanized antibody, drug conjugate thereof, and use thereof
MX2019000677A (es) Células miméticas de células b.
WO2015031598A3 (en) Therapeutic dnp derivatives and methods using same
MX2015013066A (es) Usos terapéuticos para anticuerpos contra vegfr1.
SG11201601306QA (en) An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease
MX2017005884A (es) Metodos para el tratamiento de la erc, utilizando predictores de la retencion de liquidos.
EP2959906A4 (en) ADSORBENT FOR ORAL ADMINISTRATION, MEDICAMENT FOR RENAL DISEASE, AND MEDICAMENT FOR LIVER DISEASE
EP2959908A4 (en) ORAL ADMINISTRATIVE ADSORBENT, THERAPEUTIC AGENT AGAINST CHILDING DISEASE AND THERAPEUTIC AGENT AGAINST LIVER DISEASES